31197-30-5

Basic information

• Product Name: 1-(3-Bromophenyl)piperazine
• Synonyms: 1-(3-BROMOPHENYL)-PIPERAZINE;1-(3-BROMO-PHENYL)-PIPERAZINE DIHYDROCHLORIDE;(3''-BROMOPHENYL)PIPERAZINE;1- (3- bromine phenyl) piperazine hydrochloride
• CAS NO: 31197-30-5
• Molecular Formula: C₁₀H₁₃BrN₂
• Molecular Weight: 241.13
• Product Categories: pharmacetical;Halides;Phenyls & Phenyl-Het;Piperaizine;Phenyls & Phenyl-Het;piperazines
• Mol File: 31197-30-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 121-123°C/0.5mm
• Flash Point: 167.4 °C
• Appearance: Colorless to pale yellow liquid
• Density: 1.386 g/cm³
• Vapor Pressure: 3.65E-05mmHg at 25°C
• Refractive Index: 1.575
• PKA: 8.92±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Bromophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Bromophenyl)piperazine(31197-30-5)
• EPA Substance Registry System: 1-(3-Bromophenyl)piperazine(31197-30-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 31197-30-5(Hazardous Substances Data)

Usage

General Description

1-(3-Bromophenyl)piperazine is a chemical compound recognized for its role in scientific and pharmacological research, primarily regarding the nervous system. Its chemical formula is C10H12BrN2 and it belongs to the group of phenylpiperazines, which are commonly used as building blocks in the synthesis of various pharmaceutical drugs. 1-(3-Bromophenyl)piperazine has a bromine atom bonded to a phenyl ring, demonstrating several interesting chemical properties. The behavior and impact of this chemical compound are the subject of ongoing research and its potential therapeutic applications are being examined. However, it should be handled with care due to the possible harmful effects on the skin and eyes, and ingestion or inhalation should be avoided.

InChI:InChI=1/C10H13BrN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 591-19-5 m-Bromoaniline 

Downstream Products

• 65386-40-5 1-(2-benzyl-thiazol-4-ylmethyl)-4-(3-bromo-phenyl)-piperazine 
• 78069-80-4 1-(3-Bromo-phenyl)-4-(3-nitro-pyridin-4-yl)-piperazine 
• 103247-43-4 2-[4-(3-Bromo-phenyl)-piperazin-1-yl]-N-(7-hydroxy-2,2,4,6-tetramethyl-indan-1-yl)-acetamide 
• 178928-29-5 1-[5-Methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-[4-(3-bromophenyl)-1-piperazinyl]-1-propanone 
• 78091-25-5 4-[4-(3-Bromo-phenyl)-piperazin-1-yl]-pyridin-3-ylamine 
• 291510-20-8 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine 
• 291510-89-9 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine 
• 65385-49-1 1-(3-bromo-phenyl)-4-[5-(4-chloro-phenyl)-furan-2-carbonyl]-piperazine 
• 65386-15-4 1-(3-bromo-phenyl)-4-(2-methyl-thiazol-4-ylmethyl)-piperazine 
• 926646-65-3 1-[3-(3-furyl)phenyl]piperazine 
• 926646-64-2 1-[3-(3-thienyl)phenyl]piperazine 
• 1208080-61-8 2-(4-(3-bromophenyl)piperazin-1-yl)ethanol 
• 327030-39-7 1,1-dimethylethyl 4-(3-bromophenyl)piperazine-1-carboxylate 
• 1401688-33-2 C₂₄H₂₁BrN₄ 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. Optimization of the phenylpiperazine moiety of 1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-phenylpiperazinyl-1-trans-propenes.

A series of novel 3-substituted-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propenes in order to improve the in vitro and in vivo activity of our prototype 3-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propene (2) were synthesized and evaluated by assays of growth inhibition against several tumor cell lines in vitro and antitumor activity against some tumor models when dosed both intraperitoneally and orally in vivo. Compounds 7a and 7e, the 3,5-difluorophenyl and 3,5-dichlorophenyl analogues of 2, respectively, showed significantly more potent cytotoxicity than 2 in vitro and potent antitumor activities without causing decrease of body temperature related to side effects.